Project Details
Description
A Phase 1, Open-label Study of Oral BDTX-4933 in Patients with KRAS, BRAF and Other Select RAS/MAPK Mutation Positive Neoplasms
| Status | Active |
|---|---|
| Effective start/end date | 11/28/23 → 11/30/33 |
Funding
- BLACK DIAMOND THERAPEUTICS, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.